0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Rituximab Therapy in Neuromyelitis Optica Moving Toward a Personalized Medicine Approach

W. Oliver Tobin, MB BCh, PhD1; Sean J. Pittock, MD1,2
[+] Author Affiliations
1Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota
2Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2015;72(9):974-977. doi:10.1001/jamaneurol.2015.1421.
Text Size: A A A
Published online

Extract

Neuromyelitis optica (NMO) spectrum disorders represent an evolving group of central nervous system–inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin 4 (AQP4) water channel.1 Disability is attack related and accrues incrementally, in contrast to multiple sclerosis, where disability generally occurs progressively in the later phase of the disease. Currently, immunosuppression is the mainstay of treatment in NMO. Based on relatively small retrospective and open-label prospective series, several treatments appear to be effective in preventing attacks and stabilizing disability in NMO. Unfortunately, these studies are limited by lack of randomization. The immunosuppressants most commonly prescribed for maintenance of remission include prednisone, azathioprine, mycophenolate mofetil, and rituximab.15 Breakthrough attacks should result in reevaluation of treatment strategy. Currently, outcomes appear more favorable than traditionally considered; this is believed to be related to a combination of earlier diagnosis (owing to the availability of AQP4-IgG testing, which confirms the diagnosis) and initiation of immunosuppressive medication.6 Despite optimal dosing, azathioprine, mycophenolate mofetil, and rituximab fail to prevent attacks in 53%, 25%, and 17% of patients, respectively.7 Thus, currently available treatments clearly do not offer a cure; they can also be associated with significant adverse effects. The use of rituximab for treatment of NMO is increasing, particularly in the United States. The challenge facing us is to optimize its efficacy, while limiting both cost and adverse effects.8

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,257 Views
1 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();